Is Semax Legal? What the FDA Panel Actually Voted On

Published: July 25, 2026 | By: Dr. Baghel | Category: Peptide Therapy

Updated July 25, 2026. An FDA advisory committee voted on semax on July 24. Every vote tally on this page is as reported by trade press and wire coverage, because FDA has not yet posted the official minutes or the certified vote record. I will correct these numbers against that record when it appears.

Is Semax Legal in the United States Right Now?

No, and the reason is procedural. Semax isn’t FDA-approved for any use, and no pharmacy can legally compound it for you today. An FDA advisory committee voted on July 24, 2026 to recommend adding it to the 503A compounding list, which is the first favorable federal action semax has ever received in this country. That vote and a prescription are separated by a rulemaking process that has historically run more than a year.

If you searched “is semax legal” this week, several pages on the first page of Google told you 503A pharmacies can compound it now. Those pages are wrong, and the difference is important if you’re deciding whether to buy something from a website in the meantime.

Read the indication before you read the headline. The committee evaluated semax for cerebral ischemia, migraine, and trigeminal neuralgia. The anxiety, depression, PTSD, ADHD, and cognitive uses people are interested in were not the uses FDA assessed. A listing, if it comes, would still cover them, because FDA reads the statute to say a bulks-list entry need not be limited to the use it was assessed for.

What the Committee Voted On, and What a Listing Would Permit

Here is the July 23 and 24 record for all seven peptides. The indication column reproduces the uses FDA states it evaluated in its briefing documents, which in several cases are narrower than the coverage suggests. The tallies are as reported.

Substance	Use FDA evaluated	Vote (as reported)	Can it be prescribed today?
Semax	Cerebral ischemia, migraine, trigeminal neuralgia	8-5-1 for	No
Epitalon	Insomnia	7-4-1 or 7-5-1 for	No
BPC-157	Ulcerative colitis	8-6-1 for	No
KPV	Wound healing and inflammatory conditions	8-6-1 for	No
TB-500	Wound healing	8-6-1 for	No
MOTS-c	Obesity and osteoporosis	7-5-2 for	No
DSIP (emideltide)	Sleep	6-7-1 against	No

Six of the seven cleared on the reported tallies. FDA’s own review scientists had recommended against semax on every statutory criterion the agency applies to these nominations, and its briefing document proposes that semax free base and semax acetate not be included. Reporting indicates staff recommended against the other six as well. The committee went the other way six times in two days.

You can read that two ways. One is a panel overruling its own scientists. The other is a panel deciding the agency’s evidentiary bar is the wrong bar for substances that will never have a commercial sponsor to fund registrational trials. I think the second reading is closer to right. I put the full vote-by-vote breakdown in my analysis of the 2026 FDA peptide decision.

The other thing the vote does, if FDA follows through, is broader than the indication suggests. A footnote in FDA’s briefing document states that inclusion of a substance on the 503A bulks list may not be limited to a specific use, citing the agency’s 2019 Federal Register notice at 84 FR 4696, 4701. FDA’s presentation to the committee on July 24 put it more plainly: unless specific limitations are written into the entry, the bulk drug substance can be compounded for any use, by any route.

A listing granted on a stroke and headache file would therefore, as FDA reads its own statute, permit compounding for depression, anxiety, ADHD, or cognition. FDA also records that semax was nominated for “ADHD” and “nootropic” use, and neither of those received an evidence assessment in the memorandum I read. That puts the psychiatric uses on the prescriber. I’d argue that’s where they belong.

What FDA’s “Insufficient Evidence” Finding Actually Means

Semax has a real clinical literature. It’s in Russian. Under 21 CFR 10.20(c)(2), FDA requires an accurate and complete English translation of any foreign-language material submitted for its review, and material without one doesn’t get considered. The Russian acute-stroke studies arrived without verified translations, so FDA excluded them. What remained for the cerebral ischemia question was a single conference abstract, which didn’t report the clinical endpoints FDA needed. The agency then concluded the evidence was insufficient.

The excluded studies are not small. One enrolled 110 patients after ischemic stroke on 6,000 mcg a day across two 10-day courses (PMID 29798983). Another enrolled 187 patients at different stages of cerebrovascular insufficiency (PMID 15792140). Both are an order of magnitude larger than the one abstract FDA did evaluate.

“FDA found insufficient evidence” and “the evidence was reviewed and found wanting” are different sentences, and only the first one is true here. A translation rule kept the largest studies out of the record.

That’s the pattern with semax in this country. The compound keeps getting judged on the fraction of its literature that happens to be in English.

Those Russian studies are unblinded, uncontrolled by modern standards, unregistered, and produced by investigator groups with a national stake in the compound. If they’d been translated and considered, I doubt they’d have cleared a modern bar. They still deserved to be read before they were dismissed.

The two smaller assessed indications are genuinely thin. For migraine, the human evidence is one open-label uncontrolled study in which 12 patients received a single intranasal dose at 0.5 mg/kg, and 4 of them reported the headache stopped 90 to 120 minutes later, with reduced severity in the other 8. For trigeminal neuralgia, among 16 patients with the typical form, semax produced no change in pain characteristics or trigeminal evoked potentials, and the authors concluded it “does not exhibit analgesic activity by itself.” Nine patients in a separate dental plexalgia group did respond. Both results come from Koroleva et al. 1996, indexed as PMID 8998343, whose PubMed record carries no abstract, so every number above comes from FDA’s summary of that paper.

What the Human Evidence Shows in Psychiatry

This is my end of the field. No controlled trial of semax for depression, anxiety, or PTSD has ever been run in humans. Semax has never failed a trial in psychiatry, because nobody has funded one, and there are zero registered studies on ClinicalTrials.gov, which I checked the day I published this.

A compound tested repeatedly and found ineffective has told you something real. A compound nobody has tested has told you nothing at all, and the trials here are missing for a commercial reason: semax is off-patent, so there’s no sponsor with an incentive to fund them.

The mood work that does exist is preclinical, and it’s positive. In a chronic unpredictable stress model in male rats, semax blunted both the anhedonia and the stress-related physical changes the model produces (PMID 39442746). That model is the standard rodent screen for antidepressant activity, and a good share of the antidepressants I prescribe were found through it. It’s still a rat study, and I’ll keep saying that. It’s also the result you’d want to see before spending money on a human trial. I’ve written about how these uses get marketed and what I tell patients now in my clinical review of semax and selank.

Cognition is where the human data actually sits. Two controlled studies exist. One gave 24 volunteers intranasal 1% semax or placebo and measured the brain’s default mode network (PMID 30225715). The other examined functional connectivity across 52 participants receiving selank, semax, or placebo (PMID 32342318). Both detected changes against placebo.

What those two studies establish is that intranasal semax reaches the human brain and measurably changes network activity at the doses people actually use. That’s the precondition for any cognitive claim, and plenty of supplements sold for focus can’t clear it. Neither study ran a cognitive test alongside the imaging, so the question of whether people thought or remembered any better went unasked. Somebody should ask it. It would take one modest trial.

One older paper carries most of the weight on this point. A 1997 Russian narrative review asserts that semax improved memory and attention in healthy men at 0.015 to 0.050 mg/kg intranasally (PMID 9173745), with no controlled design and no comparison group, summarizing 15 years of one research group’s own work. The claim in it may well be true.

The ADHD and Nootropic Question FDA Didn’t Assess

FDA’s record shows semax was nominated for ADHD and for nootropic use. Its briefing document contains no evidence assessment for either one. The use with the most consistent reported benefit is the use the committee spent the least time on. I treat ADHD, and this is the version of the semax question I get asked about most.

What patients tell me is specific and it repeats. People who’ve obtained semax on their own describe better sustained attention across a working day, easier task initiation, and better working memory, particularly the kind of holding-the-thread capacity that fails in the afternoon. They describe it without the appetite suppression and evening rebound that make stimulants hard for some people to tolerate. I want to be exact about what that is: it’s what patients report to me in evaluations, it’s uncontrolled, it’s subject to every bias that uncontrolled self-report carries, and it is not evidence of efficacy. It’s also consistent enough across unrelated people that I’ve stopped treating it as noise.

FDA’s own file has the mechanism. In mice, semax potentiated amphetamine-induced dopamine release in the striatum. FDA raised this as an abuse-liability concern, because increased dopaminergic tone of that kind is a response typically produced by drugs of abuse such as cocaine. Read from the ADHD side, the same finding says semax modulates the exact circuit stimulants act on, and a compound that amplifies striatal dopamine signaling is a reasonable candidate for an attention effect.

That single finding is the most encouraging thing in the semax file and the thing I’d watch hardest. A fair number of people asking me about semax are already taking a stimulant, and potentiation is the word FDA used. Combining them is the first thing I’d talk through with anyone considering it. I go through this class of interaction in more detail in my piece on taking peptides alongside psychiatric medications.

ADHD is the strongest hypothesis in the semax literature and the one with the least data behind it. One placebo-controlled trial with a proper attention battery would settle it in either direction.

Off-Label Prescribing and Compounded Semax Are Two Different Acts

I hear these two used interchangeably all the time, including by people who ought to know the difference. The distinction changes what has to be on a consent form.

Off-label prescribing starts with a drug FDA has approved. There is an FDA-reviewed manufacturing process, an approved label, established human pharmacokinetics, and known dosing. Off-label means using that drug for a purpose outside its label. I do it most days I work, and there’s a real evidence literature behind those decisions.

Semax has no approved United States label to be outside of. There’s no FDA-reviewed manufacturing process and no approved dosing. FDA’s briefing document states the agency was unable to find pharmacokinetic studies in humans following exposure to semax by any route of administration. Calling its use “off-label” imports a set of assumptions that don’t hold, and it makes the decision sound more settled than it is.

If rulemaking finishes, a semax prescription is a prescription for a compounded preparation of a substance FDA has never reviewed in a marketing application. That can be a defensible clinical decision, and for some patients I think it will be. It’s a different conversation to have, and it needs its own consent form.

What Has to Happen Before Any Pharmacy Can Compound Semax

Under section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a(b)(1)(A), a pharmacy may compound with a bulk drug substance only if one of three conditions holds. The substance must comply with an applicable United States Pharmacopeia or National Formulary monograph, and with the USP chapter on pharmacy compounding, if such a monograph exists. Failing that, it must be a component of an FDA-approved drug product. Failing both, it must appear on FDA’s 503A bulks list.

Semax meets none of the three. FDA’s briefing document says so directly: there is no applicable USP or NF drug substance monograph for semax, and it is not a component of an FDA-approved drug. It is absent from the bulks list, which is the whole reason it went to a committee.

You can check that third condition yourself in about a minute. The 503A bulks list is codified at 21 CFR 216.23, and in the version current on July 23, 2026 it contains six substances: Brilliant Blue G, cantharidin, diphenylcyclopropenone, N-acetyl-D-glucosamine, squaric acid dibutyl ester, and thymol iodide. Five of the six are restricted to topical use. There is no peptide on that list, and there never has been one. That’s the scale of what the July vote is trying to change.

Getting onto that list takes four more steps. FDA has to accept the committee’s recommendation, which it is not obligated to do. Then come a proposed rule, a public comment period, and a final rule. Comparable bulks-list rulemakings have run well over a year, and the process can end in a refusal. None of it has started. I searched the Federal Register on July 25, 2026 and found no document mentioning semax published since the vote, and no proposed rule for any of the seven peptides.

One status point gets garbled almost everywhere I look. Semax appears on FDA’s safety-risk page for bulk substances, in the table for substances nominated but withdrawn, meaning it was previously in category 2 and the nominators pulled the nomination. It is absent from the active category 2 list today. FDA’s stated concern about it remains posted there in plain language: compounded drugs containing semax “may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities,” and the agency “lacks sufficient information to know whether the drug would cause harm if administered to humans.” That page was last updated April 22, 2026. I go through what these lists do and do not mean in my guide to the 2026 FDA compounding decision.

There’s a second source of confusion in circulation. FDA published notices about bulk drug substances in May and June 2026, and vendor pages have pointed at them. Those notices concern the section 503B list, which governs outsourcing facilities and is a separate list with separate criteria. A 503B notice tells you nothing about whether a 503A pharmacy can compound semax.

If you’re working out what belongs in your own treatment plan while this plays out, that’s a conversation worth having with a prescriber. You can book an evaluation and we can go through what’s available to you today and what’s still in the pipeline.

Three Claims Circulating This Week That Are Wrong

All three are on the first page of Google as I write this. I’m not linking to them.

“Licensed 503A pharmacies can now legally compound these peptides.” A favorable committee vote is a recommendation to FDA. Adding a substance to the 503A bulks list requires notice-and-comment rulemaking that has not started.

“Available under a valid prescription through 503A pharmacies.” That is the same error, phrased to sound like a dispensing fact. Eligibility is a property of the substance itself, and writing a prescription does not create it.

“The FDA recommended semax.” The Pharmacy Compounding Advisory Committee recommended semax. It’s an outside advisory body whose members are not FDA staff, and FDA’s own briefing document proposed the opposite. When coverage says “FDA panel,” remember the panel and the agency landed in different places here.

Where I Stand, and What I’d Require

I’m optimistic about semax. That’s an unusual position for a psychiatrist to take on a compound with no human psychiatric trials behind it.

The mechanism touches the circuit stimulants act on. It came back positive in the standard rodent screen for antidepressant activity, and two controlled human studies show it reaches the brain and changes network activity at real-world doses. Russia has used it clinically for 30 years with no safety scandal attached to it.

Add a pattern of patient reports about attention that’s specific and repetitive, and you have a compound that deserves to be studied properly. That’s more than most things sold as nootropics have behind them.

What I object to is the marketing, which routinely states as settled fact things the literature doesn’t support. Overselling semax is exactly what keeps serious researchers from looking at it, and I think semax holds up better than the people selling it do.

I can’t prescribe it today, because it isn’t FDA-approved and isn’t on the 503A list. If FDA accepts the recommendation and finishes rulemaking, I intend to offer it. There’s no waitlist and no way to pre-order it, and I’m not taking requests. Any of that would be getting ahead of the law. Here is what I’d build around it.

Written Consent That Names the Gaps

The consent has to say that semax is not FDA-approved, and that a bulks-list addition establishes compounding eligibility while saying nothing about safety or effectiveness. It has to say there are no human pharmacokinetic data by any route and no controlled trials. For a psychiatric use, it has to say there is no human trial at all. A patient who understands that and still wants to try it is making an informed decision, and I’d respect it.

A Certificate of Analysis With Endotoxin Testing

The certificate of analysis has to report individual impurity identity, aggregate testing, and the exact salt form written on the prescription, because semax free base and semax acetate are different substances with different molecular weights. I wouldn’t prescribe it without an endotoxin result. This is the condition that separates a compounded prescription from a research-chemical website, and it’s the single biggest safety gain of moving semax into the legal channel.

A Bleeding Review

Semax reduced platelet aggregation by about 35% in rats given 1 mg/kg intranasally, according to the data FDA summarizes. That matters for anyone on an anticoagulant or an antiplatelet, and it matters for patients taking an SSRI or SNRI, which already carry a bleeding signal. It’s a screening question I’d ask once and act on if the answer warranted it.

Stimulant Monitoring

This follows directly from the striatal dopamine finding above. If someone is on a stimulant and adds semax, I’d want blood pressure, heart rate, sleep, and appetite tracked on a schedule rather than by recall, and I’d want to know the stimulant dose was stable first.

A Route Restriction

Only intranasal semax has published human data behind it, and that’s the route both controlled studies used. I’ve found no published study giving semax subcutaneously to a human being, and it’s sold that way constantly. Until that changes, intranasal is the only route I’d write.

If you’re in North Carolina and trying to work out whether any peptide belongs in your treatment plan, that question is worth an hour with a psychiatrist. My peptide therapy program covers the peptides that are eligible for compounding today, and I’ll tell you plainly where semax sits and what would have to change.

---

Frequently Asked Questions

Is semax legal in the United States?

Semax is not listed as a controlled substance under the Controlled Substances Act, so possessing it isn’t a criminal matter. It’s also not an approved drug, and it cannot lawfully be compounded for you by a 503A pharmacy today. Products marketed as “research chemicals” sit outside every regulated channel, with no oversight of identity, purity, or sterility. That gap is the practical argument for waiting on the legal channel.

Is semax FDA approved?

No. Semax has never been approved by FDA for any indication, and the July 24, 2026 advisory committee vote did not approve it. That vote recommended adding semax to the list of bulk substances 503A pharmacies may compound with, and FDA assessed it for cerebral ischemia, migraine, and trigeminal neuralgia. FDA still has to accept the recommendation and complete rulemaking. Drug approval is a separate process, and nobody has begun it for semax, largely because the compound is off-patent and has no commercial sponsor.

Can I get semax from a compounding pharmacy now?

No. A 503A pharmacy may only compound with a bulk substance that complies with a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list. That list is codified at 21 CFR 216.23, it contains six substances, and no peptide is among them. Semax meets none of the three conditions, and the committee vote does not change that yet. A pharmacy telling you otherwise this month is either mistaken about the rulemaking timeline or is not operating as a 503A compounder.

Does semax help with ADHD?

No controlled trial has tested it, so nobody can answer that with evidence. What exists is a mechanism and a pattern of reports. FDA documented that semax potentiated amphetamine-induced dopamine release in the striatum in mice, which is the circuit stimulants act on, and patients who’ve obtained semax on their own describe better sustained attention and working memory. FDA’s record shows semax was nominated for ADHD and nootropic use, and its briefing document contains no evidence assessment for either. One placebo-controlled trial with a proper attention battery would settle the question, and it hasn’t been run.

Did the committee recommend semax for depression or anxiety?

FDA assessed semax for cerebral ischemia, migraine, and trigeminal neuralgia. It records that semax was also nominated for ADHD and nootropic use, and its briefing document contains no evidence assessment for either. There is no human trial of semax for depression, anxiety, or PTSD indexed in PubMed. FDA has said a bulks-list entry need not be limited to a specific use, so a listing granted on a neurological file could still permit compounding for psychiatric ones unless FDA writes a limitation into the entry.

What does the reported 8-5-1 vote actually mean?

It means a majority of a standing outside advisory committee thought semax should be eligible for 503A compounding. FDA’s own briefing document proposed the opposite, and its reviewers found the evidence insufficient on every statutory criterion the agency applies. Part of that insufficiency is procedural: FDA excluded the Russian clinical literature under 21 CFR 10.20(c)(2) for lack of verified English translations. FDA weighs advisory committee recommendations and is not bound by them. Treat the tally as reported until FDA posts the certified record.

---

Disclaimer: This article is for educational purposes only and is not medical advice. Semax is not an FDA-approved medication in the United States, it is not currently available through 503A compounding pharmacies, and nothing here is an offer to prescribe it or a solicitation to request it. Any future availability depends entirely on FDA completing rulemaking. The regulatory status described here is current as of July 25, 2026 and may change. Patient experiences described in this article are uncontrolled reports and are not evidence of efficacy. All treatment decisions require a comprehensive evaluation with a licensed provider, and you should not start or stop any medication without consulting a clinician who knows your history. If you are in crisis or thinking about harming yourself, call or text 988 to reach the Suicide and Crisis Lifeline.

References

1. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23-24, 2026: Semax-Related Bulk Drug Substances. Memorandum dated May 11, 2026.
2. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Agenda, roster, voting questions, and FDA presentations. Docket FDA-2025-N-6895.
3. 21 CFR 216.23. Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act. Electronic Code of Federal Regulations, current as of July 23, 2026. Six substances listed; no peptide among them.
4. 21 CFR 10.20(c)(2). Submission of documents to FDA: requirement for an accurate and complete English translation of foreign-language material. Electronic Code of Federal Regulations. The provision under which the Russian clinical literature on semax was excluded from FDA’s review.
5. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Updated May 14, 2026.
6. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Updated April 22, 2026. Semax appears in the table for substances nominated but withdrawn.
7. Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B; 84 FR 4696 (February 15, 2019), at 4701. Cited by FDA’s briefing document for the position that a bulks-list entry may not be limited to a specific use.
8. Inozemtseva LS, Yatsenko KA, Glazova NY, et al. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. Eur J Pharmacol. 2024;984:177068. PMID 39442746.
9. Lebedeva IS, Panikratova YR, Sokolov OY, et al. Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med. 2018;165(5):653-656. PMID 30225715.
10. Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020;490(1):9-11. PMID 32342318.
11. Ashmarin IP, Nezavibat’ko VN, Miasoedov NF, et al. [A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study)]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420-430. Russian. PMID 9173745. Narrative review, no controlled design reported.
12. Gusev EI, Martynov MY, Kostenko EV, et al. [The efficacy of semax in the treatment of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3 Vyp 2):61-68. Russian. PMID 29798983. Among the studies excluded from FDA’s review for lack of a verified English translation.
13. Gusev EI, Skvortsova VI, Chukanova EI. [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(2):35-40. Russian. PMID 15792140.
14. Koroleva MV, Meĭzerov EE, Nezavibat’ko VN, et al. [Study of the analgesic effect of the semax preparation]. Biull Eksp Biol Med. 1996;122(11):527-529. Russian. PMID 8998343. English translation: Bull Exp Biol Med. 1996;122(5):1107-1109. The PubMed record carries no abstract; patient-level figures cited here are as summarized in reference 1.
15. ClinicalTrials.gov. Search: semax. Zero registered studies, verified July 25, 2026.